Amphetamine

Yes. It is a Schedule II controlled substance with a boxed warning for abuse and dependence. Taken exactly as prescribed the risk is lower, but tolerance and psychological dependence can develop, and misuse can be dangerous.

It raises blood pressure and heart rate and has been linked to arrhythmia, heart attack, stroke and sudden death, mainly in people with existing heart problems. Anyone with heart disease should be screened before starting and monitored during treatment.

MAO inhibitors are absolutely off limits within 14 days because of hypertensive crisis risk. SSRIs and other serotonergic drugs can combine with amphetamine to cause serotonin syndrome, so tell your doctor about every medication and supplement you take.

After regular or heavy use, stopping abruptly causes a crash: fatigue, depression, heavy sleepiness and increased appetite. A clinician can taper the dose to soften this.

Long-term use can modestly slow growth in children, on the order of about an inch over years of treatment. Doctors track height and weight and may use planned medication breaks.

Yes. Acidifying the urine with high-dose vitamin C or citric acid speeds amphetamine out of the body and can blunt its effect and shorten its duration, so avoid taking large amounts at the same time.

The long-term record is substantial, and it is genuinely mixed rather than either reassuring or alarming.

What is established: stimulant treatment of ADHD works, and the largest long-term follow-up found that symptom benefit was not maintained on the scale the early trials suggested once treatment became naturalistic ^[24]. That same follow-up quantified height suppression, with consistently medicated participants ending roughly an inch shorter in adulthood than those who were not; the effect is real, modest, and concentrated in those treated continuously through growth.

Cardiovascular risk is the finding that has firmed up most recently. A large study of long-term use found the risk of cardiovascular disease rose with cumulative exposure, driven mainly by hypertension and arterial disease rather than by the sudden cardiac events that dominated earlier fears ^[25]. The absolute risk in a healthy young person remains low; the point is that it is not zero and it accumulates.

Psychosis is where the amphetamines separate from the methylphenidates, and this matters for choosing between them. In a large comparison of patients starting one or the other, new-onset psychosis occurred roughly twice as often with amphetamines ^[19]. It remains an uncommon event, at about one in 660 patients, but the difference between the two drug classes is real and it is specific to this one.

Appetite suppression, weight effects and disturbed sleep persist for as long as treatment does rather than resolving, and they are the ordinary long-run costs ^[22].

The honest answer is that the studies are thinner than the confidence with which this gets discussed in either direction.

What controlled work exists mostly failed to find tolerance to the therapeutic effect. The clearest example examined the behavioural effects directly over sustained treatment and reported an absence of tolerance ^[26], and long-term trials generally show maintained benefit rather than progressive escalation ^[22]. No study has produced a figure like "tolerance develops at N weeks", and any source quoting one is quoting folklore.

What clinical practice recognises is different and equally real: some patients do lose response, and the literature on what to do about it treats that as an established clinical situation rather than a rarity ^[27]. The reconciliation is that these describe different things. Tolerance to the euphoric and appetite-suppressing effects develops quickly and is well documented; tolerance to the attentional effect at a stable therapeutic dose is much less clear, and dose increases over years are often explained by growth, changing demands or the original dose having been low.

The pattern that does reliably produce tolerance is escalation itself, especially with the higher, non-prescribed doses taken for effect rather than for function.

Watch the pattern rather than any single bad day, because normal variation looks like tolerance for about a week at a time.

The things that genuinely suggest it: the effect now wears off noticeably earlier in the day than it used to at the same dose; the dose that once produced a clear change now produces very little; you find yourself wanting an increase within weeks rather than months; and the drug's side effects persist while its benefits fade, which is the most informative combination of all, because it shows the compound is still active and the response is what changed.

Things that mimic it and are far more common: sleep debt, which degrades attention faster than any dose can compensate for; a rising workload; untreated anxiety or low mood; skipping meals, which changes absorption and blunts effect; and simple acclimatisation, where the contrast with being unmedicated fades because the medicated state has become the baseline rather than because the drug is doing less.

The practical test used clinically is a deliberate break rather than an escalation, since a break distinguishes real tolerance from the alternatives while a dose increase confirms nothing either way. That is a decision to make with the prescriber who is monitoring you, and never one to make unilaterally with Amphetamine.

Context dependent, and the honest lean is toward no.

The case for yes is narrow and real: if you have ADHD, Amphetamine treats it, and treated attention is better attention. The case for no is what happens in people who do not.

Meta-analyses of acute administration in healthy adults found the cognitive effects of methylphenidate, D-amphetamine and modafinil to be small and inconsistent across domains, rather than the broad boost the reputation implies ^[15]. More pointedly, a 2023 study found these drugs increase the LEVEL of cognitive effort people put into a hard problem while decreasing the QUALITY of that effort; participants worked harder and achieved less per unit of work, and the people who had performed best without the drug tended to lose the most ground ^[23]. That is a precise description of the common subjective report, feeling highly productive while producing less, and it is the reason the lean here is negative.

Two further considerations push the same way. The benefit is largest in those starting from the worst baseline, which means the more capable and better-rested you already are, the less there is to gain. And in a still-developing brain there is a plausible cost to the plasticity that ordinary effortful learning depends on ^[28].

So: a legitimate treatment for a diagnosed condition, and a poor general-purpose nootropic for someone without one.

There is no non-prescription compound that replaces a working stimulant for diagnosed ADHD, and that is the honest starting point; what follows is worth considering when a stimulant is not an option, is being reduced, or is being spaced out to protect sleep and appetite.

The options this site recommends are Bromantane, Phenylpiracetam, Modafinil, CE-123, Taltirelin, Caffeine, Tropisetron, Paraxanthine, Phenylalanine, L-Tyrosine and ModaFiendz.

A few notes on how they differ, because they are not interchangeable. Modafinil and ModaFiendz act on wakefulness rather than on attention directly, and are the closest thing here to a prescription-strength option. Bromantane and Phenylpiracetam are the two with the most direct stimulant-adjacent character, Phenylpiracetam noticeably so, and it loses effect quickly with daily use. CE-123 is an atypical dopamine reuptake inhibitor with a much thinner human record than the others. Taltirelin is a TRH analogue and works by a mechanism unrelated to catecholamines. Tropisetron is the non-stimulant focus option and is the right one to look at when any stimulant character is the problem. Caffeine and Paraxanthine are the everyday tier, with Paraxanthine the better choice if caffeine costs you sleep, since it is caffeine's active metabolite and skips the conversion step that varies most between people. L-Tyrosine and Phenylalanine are catecholamine precursors, useful mainly under acute stress or sleep loss rather than as daily nootropics; L-Tyrosine has the better evidence of the two.